Bank Of New York Mellon Corp Actinium Pharmaceuticals, Inc. Transaction History
Bank Of New York Mellon Corp
- $521 Trillion
- Q1 2024
A detailed history of Bank Of New York Mellon Corp transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 67,366 shares of ATNM stock, worth $549,032. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,366
Previous 114,810
41.32%
Holding current value
$549,032
Previous $583 Million
9.56%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ATNM
# of Institutions
72Shares Held
6.65MCall Options Held
369KPut Options Held
148K-
Black Rock Inc. New York, NY1.71MShares$13.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.45MShares$11.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA596KShares$4.86 Million0.0% of portfolio
-
State Street Corp Boston, MA551KShares$4.49 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL231KShares$1.88 Million0.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $205M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...